European Union - English - EMA (European Medicines Agency)

cipla (eu) limited - olanzapine - schizophrenia; bipolar disorder - psycholeptics - adultsolanzapine is indicated for the treatment of schizophrenia.olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.olanzapine is indicated for the treatment of moderate to severe manic episode.in patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levocetirizine dihydrochloride - film-coated tablet - 5mg - antihistamine for systemic use, piperazine derivative, - symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis) and urticaria

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - etoposide - concentrate for soln for inf - 20 mg/ml - podophyllotoxin derivatives - it is indicated in adults for the management of: resistant non-seminomatous testicular tumours in combination with other chemotherapeutic agents; small cell lung cancer, in combination with other chemotherapeutic agents; acute monoblastic leukaemia (aml m5) and acute myelomonoblastic leukaemia (aml m4) when standard induction therapy has failed (in combination with other chemotherapeutic agents).

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - paclitaxel - concentrate for solution for infusion - 6 milligram(s)/millilitre - taxanes - plant alkaloids and other natural products, taxanes - it is indicated for the treatment of patients with carcinoma. see spc for all therapeutic indications

Malta - English - Medicines Authority

cipla (eu) limited hillbrow house, hillbrow road, esher, surrey, kt10 9nw, united kingdom - cyclizine hydrochloride - tablet - cyclizine hydrochloride 50 mg - antihistamines for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - imatinib mesilate - capsules hard - 400 milligram - other cytostatics - antineoplastic agents; protein kinase inhibitor - it is indicated for the treatment of:
paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid; leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;
paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated; phase or blast crisis;
adult patients with ph+ cml in blast crisis;
adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;
adult patients with relapsed or refractory ph+ all as monotherapy;
adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived; growth factor receptor (pdgfr) gene re-arrangements;
adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr
rearrangement

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 250 milligram - other antiepileptics

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 500 milligram - other antiepileptics

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 750 milligram - other antiepileptics

Ireland - English - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - levetiracetam - film coated tablet - 1000 milligram - other antiepileptics